The Min Lu Research Group

Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
State Key Laboratory of Omics and Disease (formerly State Key Laboratory of Medical Genomics)

The Min Lu Research Group

Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
State Key Laboratory of Omics and Disease (formerly State Key Laboratory of Medical Genomics)

Huaxin Song

Research Associate

Research Direction

P53 targeted therapy

Lead The Project

2024 National Science and Technology Major Project (2024ZD0519603), project leader

2024 National Natural Youth (82403726), host

2024 Shanghai Science and Technology Commission Qimingxing (24YF2726100), host

Special Support from the 2023 China Postdoctoral Science Foundation (2023TQ0218), led by

2023 China Postdoctoral Science Foundation General Support (2023M732277) Hosted by

Hosted by the 2022 Ruijin Hospital Youth Fund Cultivation Program (KY2023431)

Honors And Awards

2024 Shanghai Science and Technology Commission Qimingxing Project Sail Special Project

2023 National Postdoctoral Researcher Program

Excellent in the assessment of the 2024 National Postdoctoral Research Program (83/4730)

2023 Shanghai ‘Super Postdoctoral Fellow’, 300000 yuan

2023 Shanghai Jiao Tong University School of Medicine Postdoctoral Incentive Program

2019 Shanghai Jiao Tong University First Class Scholarship

2018 “Chen Zhu. Chen Saijuan” Outstanding Talent Award Fund

2017 Shanghai Jiao Tong University First Class Scholarship
Invention Patent
  1. Song H#, Xiao S#, Wu J#, Lu M*. Drugging p53: Barriers, Criteria, and Prospects. Cancer Discov. 2024 Nov 1;14(11):2055-2060（第一作者，IF=30.6）
  2. Song H#, Wu J#, Tang Y#, …, Lu M*. Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Sci Transl Med. 2023 Apr 5;15(690):eabn9155（第一作者，IF=17.1）
  3. WuJ#, Song H#, Xiao S#, Lu M*. Heterogeneity of p53 mutations necessitates differentiation with p53-rescue therapies. Nat Rev Cancer. （共同第一，IF = 72.5）
  4. Xiao S#, Shi F#,Song H#, …, Lu M*. Characterization of the generic mutant p53-rescue compounds in a broad range of assays. Cancer Cell. 2024 Mar 11;42(3):325-327（共同第一，IF=48.8）
  5. Jiabing Li#, Shuang Zhang#, …, and Min Lu*. Pharmacological rescue of mutant p53 triggers spontaneous tumor regression via immune responses. Cell Rep Med. 2025 Mar 18;6(3):101976（共同通讯，IF=11.7）
  6. Liang Y#, An Q#, Song H#*, …, Lu M*. AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell Selectivity.J Med Chem. 2023 Dec 28;66(24):16579-16596（共同通讯，IF=7.3）
  7. Tang Y#, Song H#,Wang Z#, …, Lu M*. Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations. Cell Rep. 2022 Apr 12;39(2):110622（共同第一，IF=10.0）
  8. Chen S#, Wu JL#, Liang Y#, …, Lu M*. Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. Cancer Cell. 2021 Feb 8;39(2):225-239.e8（共同作者，IF=48.8）
  9. Wu J#, Song H#, Wang Z#, Lu M*. Three optimized assays for the evaluation of compounds that can rescue p53 mutants. STAR Protoc. 2021 Jul 27;2(3):100688（共同第一，IF=1.3）
  10. Yan N#, Li Y#, Xing Y, …, Lu M*. Developmental arsenic exposure impairs cognition, directly targets DNMT3A, and reduces DNA methylation. EMBO Rep. 2022 Jun 7;23(6):e54147（共同作者，IF=9.4）
  11. Li J#, Xiao S#, Shi F#, …, Lu M*. Arsenic trioxide extends survival of Li-Fraumeni syndrome mimicking mouse. Cell Death Dis. 2023 Nov 29;14(11):783（共同作者，IF=9.0）
  12. Wu J#, Li Y#, Wu J#, …, Lu M*. Decitabine activates type I interferon signaling to inhibit p53-deficient myeloid malignant cells. Clin Transl Med. 2021 Nov;11(11):e593（共同作者，IF=11.5）
  13. Wu J#, Liang Y#, Tan Y, …, Lu M*. CDK9 inhibitors reactivate p53 by downregulating iASPP. Cell Signal. 2020 Mar;67:109508（共同作者，IF=4.0）

The Min Lu Research Group

Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
State Key Laboratory of Omics and Disease (formerly State Key Laboratory of Medical Genomics)
  • 021-64370045 
  • min.lu@@shsmu.edu.cn
  • No. 197, Ruijin Er Road, Huangpu District, Shanghai, China

The Min Lu Research Group©️Copyright